The Journal of
Clinical Psychiatry

Depression (MDD)

Insights April 6, 2021

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Roueen Rafeyan, MD, DFAPA, FASAM; George I. Papakostas, MD; W. Clay Jackson, MD, DipTh; Madhukar H. Trivedi, MD

J Clin Psychiatry 2020;81(3):OT19037BR3

Learn how to talk with patients who have major depressive disorder about antipsychotic treatment in a way that is clear and balanced and addresses patients’ potential concerns about taking antipsychotic medication.

Read the eReport

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

View current Issue

Insights

Patient Functioning and Life Engagement: Treatment Goals in MDD

September 7, 2022

Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...

Christoph U. Correll, Zahinoor Ismail, Roger S. McIntyre, et al

Insights

Measurement-Based Care for Depressive Disorders: Meta-Analysis of RCTs Shows Efficacy

May 17, 2022

Dr Lam explains in this video how for patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.

Raymond W. Lam

Insights

Progression of Symptoms Over the Course of Bipolar Disorder

April 13, 2021

Dr Joseph F. Goldberg discusses how symptoms and clinical presentation change over time in people with bipolar disorder, beginning from the prodromal phase

Joseph F. Goldberg

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Read the Current Issue

Changes in Cognition in Patients With Schizophrenia

Diagnostic Assessment via Telehealth vs Face-to-Face

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Bridge Symptoms Between Borderline Personality and PTSD

Gepirone-ER and Sexual Function in Patients with MDD

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

ELSEWHERE:

FOLLOW US:

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Read the Current Issue

Changes in Cognition in Patients With Schizophrenia

Diagnostic Assessment via Telehealth vs Face-to-Face

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Bridge Symptoms Between Borderline Personality and PTSD

Gepirone-ER and Sexual Function in Patients with MDD

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

Related Articles

Patient Functioning and Life Engagement: Treatment Goals in MDD

Measurement-Based Care for Depressive Disorders: Meta-Analysis of RCTs Shows Efficacy

Progression of Symptoms Over the Course of Bipolar Disorder

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles